annb0t
Top 20
SYDNEY, Dec. 1, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication of positive preclinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for multiple forms of cancer. Kazia Therapeutics Limited Logo (PRNewsfoto/Kazia Therapeutics Limited)
The publication, by Michael Paillasse and colleagues, summarizes a large body of preclinical research conducted princip...
>>> Read more: COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL
The publication, by Michael Paillasse and colleagues, summarizes a large body of preclinical research conducted princip...
>>> Read more: COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL
